Swiss drug giant Roche (RHHBY.PK)
hasn't had the best run of luck lately. Having moved past significant
issues with the Avastin franchise in 2011, the company failed in its
efforts to acquire Illumina (ILMN)
and now investors have to digest the surprising Phase 3 failure of its
cholesterol drug dalcetrapib. Not only does this clinical failure remove
a fair bit of the wind from Roche's sails, but it should also improve
the outlook for Merck (MRK) and Lilly (LLY).
Please click here to continue:
Roche's Pain May Be Merck's Gain
No comments:
Post a Comment